CASE STUDY | PRECLINICAL RESEARCH
Oridivus ORD002 Advancing A Novel, Regenerative Oral Wound Therapy
Veranex designed and executed the large preclinical oral wound healing model that helped Oridivus generate the comparative evidence needed to support ORD002, an investigational fingolimod (FTY720) loaded electrospun nanofiber scaffold through the regulatory progress.3
Key contributor: Kirsten Reeves, Senior Preclinical Program Manager at Veranex and Preclinical Study Director for Oridivus ORD002.
Preclinical Research for Regenerative Oral Wound Healing
Oridivus is developing ORD002, an investigational fingolimod (FTY720) loaded electrospun nanofiber scaffold for oral mucosa wound healing. To move the program beyond early bench and small-model evidence, Veranex designed and executed a large preclinical oral wound healing model that generated the comparative data needed to support continued development under the FDA 505(b)(2) pathway.1,3
Services
- Preclinical Research
Industries
- Drug Delivery & Biopharmaceuticals
- Regenerative Medicine
- Oral & Craniofacial Wound Healing
The Challenge
Oridivus’ investigational ORD002 fingolimod regenerative therapy showed promise in early research, but advancing the program required comparative evidence from a large preclinical oral wound healing model that better reflects the clinical challenge. The key was designing the right model, from wound placement and size to surgical execution, to generate reliable healing data while maintaining model integrity and welfare. The slower, more human-like healing timeline of large preclinical models also required carefully selected study windows.
The Solution
Veranex designed and executed the large preclinical oral wound healing model, drawing on experience in dental and wound-healing research. The team optimized wound placement and sizing, surgical procedures, and recovery to support a valid, comparable ORD002 against injury-only and platelet-rich plasma (PRP) controls . By combining model selection, study design, and surgical expertise, Veranex helped turn promising early science into actionable translational evidence the sponsor could trust.
“[This porcine model] work wouldn't have been possible without the expertise and support at Veranex.
Thank you to the Veranex team for their contributions to the preclinical study design and execution. Your facilities and scientific rigor help translate bench science into the kind of evidence that moves therapeutics forward.”
Steven Goudy, MD, MBA
Founder and Chief Medical Officer, Oridivus
Why Oral Wound Healing Matters
-
Why is oral wound healing such a meaningful challenge?
Delayed healing can lead to complications, repeat procedures, and longer recovery. In indications like cleft-palate repair, improving tissue closure can meaningfully impact patient outcomes.2
-
Why is this such a difficult environment to treat?
The oral cavity is constantly exposed to moisture, mechanical stress, and bacterial load. That makes durable healing harder to achieve and raises the bar for therapies designed to support regeneration.
-
Why does stronger preclinical evidence matter here?
Promising early science is not enough on its own. Sponsors need clinically relevant comparative evidence to understand performance against relevant comparators and make more confident next-stage development decisions.
How Veranex Designed and Delivered the Study
Veranex supported the program from model selection and study design through execution and evidence generation, helping create a large preclinical oral wound healing model designed to deliver meaningful comparative data.
Project Phase 1
Study Design for Translational Relevance
The team defined the model approach, study timeline, healing assessments, and comparison strategy needed to close the gap between promising early findings and the next stage of development.
Learn more about how model selection can shape the strength and translational relevance of preclinical evidence.
Project Phase 2
Controlled Study Execution
The study was executed in a controlled environment that enabled reliable comparison across treatment groups. Surgical expertise, facilities, and operational coordination helped maintain consistency across wound creation, treatment delivery, and follow-up for ORD002, platelet-rich plasma, and injury-only controls.
Project Phase 3
Healing Assessment and Comparative Data Generation
The team generated comparative wound-healing and tissue-response data across the study period by tracking closure and tissue quality over time. The resulting evidence gave the sponsor a clearer, more clinically relevant view of how ORD002 performed relative to injury-only and platelet-rich plasma controls, helping make the next stage of development more actionable.
Outcome & Results
Outcomes That Advanced the Program
The study generated comparative evidence that supports continued development under Oridivus' planned FDA 505(b)(2) pathway.3
In a porcine oral wound healing pilot study (4 animals; each received all three treatments), ORD002 showed the greatest average wound closure by day 13, with a 54.07% reduction in wound area compared with 44.64% for injury-only and 35.77% for platelet-rich plasma (PRP) controls.1
These findings gave the sponsor stronger comparative preclinical evidence to inform continued development and associated investment with greater confidence.
ORD002 is investigational and has not been approved by the U.S. Food and Drug Administration (FDA).
Why Innovators Choose Veranex for Translational Preclinical Research
Promising early science only matters if it translates into evidence that can support the next stage of development.
Veranex helps innovators design and execute the studies that turn early potential into defensible preclinical proof.
Benchtop and small-model findings do not automatically translate into larger translational study design, timelines, procedures, or outcomes. Experienced model selection and execution can help reduce repeat work, protect timelines, and strengthen development decisions.
Integrated study design through execution support for large preclinical model translational studies
Scientific, surgical, and operational expertise in complex wound healing research
Experience selecting and designing models to generate controlled comparative evidence in clinically relevant settings
Support for programs moving beyond early findings toward more confident development and regulatory decisions
References
- Toma AI, Shah DC, Duke VR, et al. Investigating FTY720-NF immunomodulation of key lipid, gene, and protein mediators to enhance oral tissue regeneration. Biomaterials Advances. 2026. https://doi.org/10.1016/j.bioadv.2026.214952 (Veranex acknowledged for the porcine oral wound healing study.)
- Oronasal fistula rate after cleft-palate repair: Bykowski et al., Cleft Palate Craniofac J 2015; Cohen et al., Plast Reconstr Surg 1991 (as cited in the primary article).
- ORD002 development stage, pediatric mission, and 505(b)(2) pathway: Oridivus public statements. https://www.oridivus.com/
Need defensible preclinical evidence to move your therapy forward?
Our preclinical teams design and execute translational studies that help regenerative medicine and biopharma innovators move beyond early findings with greater confidence.